Rozlytrek can be prescribed in big 5. According to related industries, Rozlytrek, a target anticancer drug for NTRK in Roche, Korea, passed the DC of Big 5, including Samsung Medical Center, Seoul National University Hospital, Seoul St. Mary's Hospital, and Sinchon Severance Hospital. Bayer Korea's Vitrakvi has already entered the Big 5 hospitals, and both drugs have been covered by insurance benefits since April this month, so competition for full-fledged prescriptions has begun. The two drugs can actually be applied to most carcinomas where the NTRK gene has been identified. However, there are restrictions on standards. The subjects of salary administration of the two drugs were limited to cancer types mentioned in